Pasar al contenido principal

POLARIZACION Y RE-PROGRAMACION DE MACROFAGOS HUMANOS POR SEROTONINA: PAPEL DEL ARYL HYDROCARBON RECEPTOR (AHR) Y LOS FACTORES LXR Y SREBP

PID2020-114323RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of LXR controls the polarization of human inflammatory macrophages through upregulation of MAFB

  • González de la Aleja, Arturo
  • Herrero, Cristina
  • Torres-Torresano, Mónica
  • Schiaffino, María Teresa
  • Del Castillo, Alejandro
  • Alonso, Bárbara
  • Vega Palacios, Miguel A.
  • Puig-Kröger, Amaya
  • Castrillo, Antonio
  • Corbí, Angel L.
13 p.-6 fig., Monocyte-derived macrophages contribute to pathogenesis in inflammatory diseases and their effector functions greatly depend on the prevailing extracellular milieu. Whereas M-CSF primes macrophages for acquisition of an anti-inflammatory profile, GM-CSF drives the generation of T cell-stimulatory and pro-inflammatory macrophages. Liver X Receptors (LXRα and LXRβ) are nuclear receptors that control cholesterol metabolism and regulate differentiation of tissue-resident macrophages. Macrophages from rheumatoid arthritis and other inflammatory pathologies exhibit an enriched LXR pathway, and recent reports have shown that LXR activation raises pro-inflammatory effects and impairs the acquisition of the anti-Inflammatory profile of M-CSF-dependent monocyte-derived macrophages (M-MØ). We now report that LXR inhibition prompts the acquisition of an anti-inflammatory gene and functional profile of macrophages generated within a pathological environment (synovial fluid from Rheumatoid Arthritis patients) as well as during the GM-CSF-dependent differentiation of human monocyte-derived macrophages (GM-MØ). Mechanistically, inhibition of LXR results in macrophages with higher expression of the v-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog B (MAFB) transcription factor, which governs the macrophage anti-inflammatory profile, as well as over-expression of MAFB-regulated genes. Indeed, gene silencing experiments on human macrophages evidenced that MAFB is required for the LXR inhibitor to enhance the anti-inflammatory nature of human macrophages. As a whole, our results demonstrate that LXR inhibition prompts the acquisition of an anti-inflammatory transcriptional and functional profile of human macrophages in a MAFB-dependent manner, and propose the use of LXR antagonists as potential therapeutic alternatives in macrophage re-programming strategies during inflammatory responses., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades (SAF2017-83785-R to MAV and ALC, PID2020-114323RB-I00 to ALC), Ministerio de Ciencia, Innovación y Universidades y Fondo Europeo de Desarrollo Regional (FEDER) (SAF2017-90604-REDT and PID2019-104284RBI00/AEI/https:// doi. org/ 10. 13039/ 50110 00110 33 to AC), Dirección General de Innovación e Investigación Tecnológica de la Comunidad de Madrid (RETARACOVID, P2022/BMD-7274) to AC, ALC and APK, Instituto de Salud Carlos III (Grant PI20/00316 to APK), and Red de Enfermedades Inflamatorias (RICORS RD21/0002/0034) from Instituto de Salud Carlos III and cofinanced by the European Regional Development Fund “A way to achieve Europe” (ERDF) and PRTR to APK. MTS was funded by a “Contrato Post-Formación Sanitaria Especializada” of the “Programa Intramural de Impulso a la I+D+i 2022 (IiSGM)” (2022-II-POSTFSE-03). AGA was funded by FPU predoctoral fellowship (FPU16/02756) from Ministerio de Universidades and RICORS-ICTUS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TLR7 activation in M-CSF-dependent monocyte-derived human macrophages potentiates inflammatory responses and prompts neutrophil recruitment

  • Simón-Fuentes, Miriam
  • Herrero, Cristina
  • Acero-Riaguas, Lucía
  • Nieto, Concha
  • Lasala, Fátima
  • Labiod, Nuria
  • Luczkowiak, Joanna
  • Alonso, Bárbara
  • Delgado, Rafael
  • Colmenares, María
  • Corbí, Angel L.
  • Domínguez-Soto, Ángeles
23 p.-5 fig., Toll-like receptor 7 (TLR7) is an endosomal Pathogen-Associated Molecular Pattern (PAMP) receptor that senses single-stranded RNA (ssRNA) and whose engagement results in the production of type I IFN and pro-inflammatory cytokines upon viral exposure. Recent genetic studies have established that a dysfunctional TLR7-initiated signaling is directly linked to the development of inflammatory responses. We present evidences that TLR7 is preferentially expressed by monocyte-derived macrophages generated in the presence of M-CSF (M-MØ). We now show that TLR7 activation in M-MØ triggers a weak MAPK, NFκB and STAT1 activation and results in low production of type I IFN. Of note, TLR7 engagement re-programs MAFB+ M-MØ towards a pro-inflammatory transcriptional profile characterized by the expression of neutrophil-attracting chemokines (CXCL1-3, CXCL5, CXCL8), whose expression is dependent on the transcription factors MAFB and AhR. Moreover, TLR7-activated M-MØ display enhanced pro-inflammatory responses and a stronger production of neutrophil-attracting chemokines upon secondary stimulation. As aberrant TLR7 signaling and enhanced pulmonary neutrophil/lymphocyte ratio associate with impaired resolution of virus-induced inflammatory responses, these results suggest that targeting macrophage TLR7 might be a therapeutic strategy for viral infections where monocyte-derived macrophages exhibit a pathogenic role., This work was supported by Grant PID2020-114323RB-I00 from Ministerio de Ciencia e Innovación, “Ayudas FUNDACIÓN BBVA a equipos de investigación científica SARS-CoV-2 y COVID-19” and Grant 201619.31 from Fundació La Marató/TV3 to ALC, grants from the Instituto de Investigación Carlos III, ISCIII,(PI2100989), European Commission Horizon 2020 FP (Project VIRUSCAN FETPROACT-2016: ID 731868), Horizon Europe FP (Project EPIC-CROWN-2 ID: 101046084) and Fundación Caixa-Health Research (Project StopEbola HR18-00469) to RD, and Red de Investigación en Enfermedades Reumáticas (RIER, RD16/0012/0007), and co-financed by the European Regional Development Fund “A way to achieve Europe” (ERDF) to ALC. This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global). MSF was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (Grant PRE2018-083396)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MAFB shapes human monocyte-derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression

  • Simón-Fuentes, Miriam
  • Ríos, Israel
  • Herrero, Cristina
  • Lasala, Fátima
  • Labiod, Nuria
  • Luczkowiak, Joanna
  • Roy-Vallejo, Emilia
  • Fernández de Córdoba-Oñate, Sara
  • Delgado-Wicke, Pablo
  • Bustos, Matilde
  • Fernández-Ruiz, Elena
  • Colmenares, María
  • Puig-Kröger, Amaya
  • Delgado, Rafael
  • Vega Palacios, Miguel A.
  • Corbí, Angel L.
  • Domínguez-Soto, Ángeles
22 p.-6 fig.1 graph. abst., Monocyte-derived macrophages, the major source of pathogenic macrophages in COVID-19, are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (GM-CSF), which promote the generation of antiinflammatory/immunosuppressive MAFB+ (M-MØ) or proinflammatory macrophages (GM-MØ), respectively. The transcriptional profile of prevailing macrophage subsets in severe COVID-19 led us to hypothesize that MAFB shapes the transcriptome of pulmonary macrophages driving severe COVID-19 pathogenesis. We have now assessed the role of MAFB in the response of monocyte-derived macrophages to SARS-CoV-2 through genetic and pharmacological approaches, and we demonstrate that MAFB regulated the expression of the genes that define pulmonary pathogenic macrophages in severe COVID-19. Indeed, SARS-CoV-2 potentiated the expression of MAFB and MAFB-regulated genes in M-MØ and GM-MØ, where MAFB upregulated the expression of profibrotic and neutrophil-attracting factors. Thus, MAFB determines the transcriptome and functions of the monocyte-derived macrophage subsets that underlie pulmonary pathogenesis in severe COVID-19 and controls the expression of potentially useful biomarkers for COVID-19 severity., This work was supported by grant PID2020-114323RB-I00 from Ministerio de Ciencia e Innovación to ALC; “Ayudas FUNDACIÓN BBVA a equipos de investigación científica SARS-CoV-2 y COVID-19” to MAV and ALC; Dirección General de Innovación e Investigación Tecnológica de la Comunidad de Madrid (RETARACOVID, P2022/BMD-7274) to ALC, APK, EFR, and RD; Instituto de Salud Carlos III (grant PI20/00316 to APK, grant PI2100989 to RD, grant PI22/00428 to EFR); Red de Enfermedades Inflamatorias (RICORS RD21/0002/0034) from Instituto de Salud Carlos III and cofinanced by the European Regional Development Fund “A way to achieve Europe” (ERDF) and PRTR to APK; European Commission Horizon 2020 FP (Project VIRUSCAN FETPROACT-2016: ID 731868); Horizon Europe FP (Project EPIC-CROWN-2 ID: 101046084); and Fundación Caixa-Health Research (Project StopEbola HR18-00469) to RD. This research was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). MSF was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (grant PRE2018-083396). ERV was funded by a Rio-Hortega grant CM19/00149 from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and cofunded by the ERDF. SFDCO was funded by the PREDINMUN-COVID Grant (Fondo Supera COVID-19 from Banco de Santander and CRUE) and PDW by PI19/00096., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GSK3β inhibition prevents macrophage reprogramming by high-dose methotrexate

  • Ríos, Israel
  • López-Navarro, Baltasar
  • Torres-Torresano, Mónica
  • Soler Palacios, Blanca
  • Simón-Fuentes, Miriam
  • Domínguez-Soto, Ángeles
  • Muller, Ittai B.
  • Jansen, Gerrit [
  • Corbí, Angel L.
  • Puig-Kröger, Amaya
14 p.-6 fig., Methotrexate (MTX) is an antifolate drug used as a chemotherapeutic agent for acute lymphoblastic leukemia, where MTX improves patients' prognosis. Macrophage reprogramming is being increasingly assessed as an antitumor therapeutic strategy. However, and although MTX limits the pathogenic action of macrophages in chronic inflammatory diseases, its effects on tumor-promoting macrophages have not been previously explored. We now report that MTX shapes the transcriptional and functional profile of M-CSF-dependent human macrophages, whose transcriptome is highly enriched in the gene signature that defines pathogenic tumor-associated macrophages ("large TAM"). Specifically, MTX prompted the acquisition of the gene signature of antitumoral "small TAM" and skewed macrophages toward an IL-6high IFNβ1high IL-10low phenotype upon subsequent stimulation. Mechanistically, the MTX-induced macrophage reprogramming effect correlated with a reduction of the M-CSF receptor CSF1R expression and function, as well as a diminished expression of MAF and MAFB transcription factors, primary determinants of pro-tumoral macrophages whose transcriptional activity is dependent on GSK3β. Indeed, the ability of MTX to transcriptionally reprogram macrophages toward an antitumoral phenotype was abrogated by inhibition of GSK3β. Globally, our results establish MTX as a macrophage reprogramming drug and indicate that its ability to modulate macrophage polarization may also underlie its therapeutic benefits. Since GSK3β inhibition abrogates the reprogramming action of MTX, our results suggest that the GSK3β-MAFB/MAF axis constitutes a target for the macrophage-centered antitumor strategies., This work was supported by Grant PI17/00037 and PI20/00316 from Instituto de Salud Carlos III to A.P.K., Grant PID2020-114323RB-I00 from Ministerio de Ciencia e Innovación to A.L.C., “Ayudas FUNDACIÓN BBVA a equipos de investigación científica SARS-CoV-2 y COVID-19” to A.L.C., and Red de Investigación en Enfermedades Reumáticas (RIER, RD16/0012/0007), and cofinanced by the European Regional Development Fund “A way to achieve Europe” (ERDF), to A.L.C. and A.P.K. This research work was funded by the European Commission-NextGenerationEU, through CSICs Global Health Platform (PTI Salud Global). This work was supported in part by a grant from the Dutch Society for Clinical Chemistry (NVKC) to I.B. Muller and R. de Jonge. M.S.F. was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (Grant PRE2018-083396)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reprogramming of GM-CSF-dependent alveolar macrophages through GSK3 activity modulation

  • Ríos, Israel
  • Herrero, Cristina
  • Torres-Torresano, Mónica
  • López-Navarro, Baltasar
  • Schiaffino, María Teresa
  • Díaz Crespo, Francisco
  • Nieto-Valle, Alicia
  • Samaniego, Rafael
  • Sierra-Palomares, Yolanda
  • Oliver, Eduardo
  • Revuelta-Salgado, Fernando
  • García-Luján, Ricardo
  • Sánchez-Mateos, Paloma
  • Delgado, Rafael
  • Puig-Kröger, Amaya
  • Corbí, Angel L.
Monocyte-derived macrophages recruited into inflamed tissues can acquire an array of functional states depending on the extracellular environment. Since the anti-inflammatory/pro-fibrotic macrophage profile is determined by MAFB, whose activity/protein levels are regulated by GSK3, we addressed the macrophage reprogramming potential of GSK3 modulation. GM-CSF-dependent (GM-MØ) and M-CSF-dependent monocyte-derived macrophages (M-MØ) exhibited distinct levels of inactive GSK3, and inhibiting GSK3 in GM-MØ led to the acquisition of transcriptional, phenotypic, and functional properties characteristic of M-MØ (enhanced expression of IL-10 and monocyte-recruiting factors, and higher efferocytosis). These reprogramming effects were also observed upon GSK3α/β knockdown and through GSK3 inhibition in ex vivo isolated human alveolar macrophages (AMØ). Notably, GSK3 downmodulation potentiated the transcriptional signature of interstitial macrophages (IMØ) while suppressing the AMØ-specific gene profile. Indeed, heightened levels of inactive GSK3 and MAFB-dependent proteins were observed in severe COVID-19 patients' lung macrophages, highlighting the GSK3-MAFB axis as a therapeutic target for macrophage reprogramming., This work was supported by grant PID2020- 114323RB- I00 from Ministerio de Ciencia e Innovación to ALC, Dirección General de Innovación e Investigación Tecnológica de la Comunidad de Madrid (RETARACOVID, P2022/BMD- 7274) to ALC, APK, PS- M, and RD, Instituto de Salud Carlos III (Grant PI23/00224 to APK, Grant PI21/00989 to RD), Red de Enfermedades Inflamatorias (RICORSRD21/0002/0034) from Instituto de Salud Carlos III and cofinanced by the Euopean Regional Devel-opment Fund 'A way to achieve Europe' (ERDF) and PRTR to APK, and PID2021- 123167OB- I00 from Ministerio de Ciencia, Innovación y Universidades and CSIC Talent Attraction program (20222AT010) to EO. This research work was also funded by the European Commission – NextGenerationEU (Regu-lation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). AN- V was funded by YEI program contract from Comunidad de Madrid (PEJ- 2021- AI/BMD- 23327). IR was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (Grant PRE2021- 097080). Figures were created with Biorender.com., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Reprogramming of human monocyte-derived macrophages through GSK3modulation, Reprogramación de macrófagos humanos derivados de monocitos mediante la modulación de GSK3

  • Ríos Hernández, Rodolfo Israel
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, leída el 21-01-2026, [EN] Macrophages, derived from circulating monocytes recruited to inflammatory sites, exhibit remarkable functional plasticity dictated by their microenvironment. Understanding the molecular mechanisms controlling their functional versatility is crucial for developing novel immunomodulatory therapies. This study focuses on the anti-inflammatory/pro-fibrotic macrophage phenotype, demonstrating its critical dependence on the transcription factor MAFB. We have established that glycogen synthase kinase 3 (GSK3) acts as a central regulator of macrophage specialization by controlling MAFB protein stability via proteasomal degradation. We have also revealed a fundamental dichotomy between granulocyte-macrophage colonystimulating factor (GM-CSF)-differentiated macrophages (GM-MØ) and macrophage colonystimulating factor (M-CSF)-differentiated macrophages (M-MØ). M-MØ exhibit higher levels of inhibitory phosphorylation on GSK3α (Ser21) and GSK3β (Ser9) and consequently, significantly elevated MAFB protein expression..., [ES] Los macrófagos, derivados de monocitos circulantes reclutados en sitios inflamatorios, exhiben una notable plasticidad funcional dictada por su microambiente. Comprender los mecanismos moleculares que controlan esta versatilidad es fundamental para desarrollar nuevas terapias inmunomoduladoras. Este estudio se centra en el fenotipo antiinflamatorio/profibrótico de los macrófagos, y demuestra su dependencia crítica del factor de transcripción MAFB. Se ha establecido que la glucógeno sintasa quinasa 3 (GSK3) actúa como regulador central de la especialización de los macrófagos al controlar la estabilidad de la proteína MAFB a través de la degradación proteasómica. En primer lugar, hemos revelado la existencia de una dicotomía fundamental entre los macrófagos diferenciados por el factor estimulante de colonias de granulocitos y macrófagos (GM-CSF) (GMMØ)y los macrófagos diferenciados por el factor estimulante de colonias de macrófagos (M-CSF)(M-MØ). Los M-MØ presentan niveles más altos de fosforilación inhibidora en GSK3α (Ser21) yGSK3β (Ser9) y, en consecuencia, una expresión significativamente más elevada de la proteína MAFB..., This work was supported by grant PID2020-114323RB-I00 from Ministerio de Ciencia e Innovación to ALC, and RETARACOVID (P2022/BMD-7274) from Comunidad de Madrid. to ALC. Israel Ríos was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (Grant PRE2021-097080)., Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares - líneas celulares primarias